Law360, New York (September 30, 2005, 12:00 AM EDT) -- GlaxoSmithKline will go back to court to defend one of the patents for its anti-nausea drug Zofran, the challenge coming this time from generic drug maker Eon Laboratories.
On August 9, Glaxo received notice that Eon, which recently merged with Sandoz Laboratories, had filed an Abbreviated New Drug Application seeking permission to produce a generic version of the drug.
In the complaint, Glaxo contends that Eon’s ANDA violates a patent it holds for “process and composition using ondansetron,” the active ingredient in Zofran. Glaxo was awarded...
Glaxo Sues To Protect Zofran Patent
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
